Inclusion Criteria:

• * Subjects must have suspected high grade glioma by MRI
• * Subjects must have received no prior therapies for this disease.
• * Patients must be considered appropriate candidates for LITT.
• * Karnofsky Performance status ≥ 60%
• * Subjects must have normal organ and marrow function as defined below. Measures of function must be within 14 days prior to registration.
• * Absolute neutrophil count (ANC) ≥ 1500 cells/mm3, platelets ≥ 100,000 cells/mm3, hemoglobin ≥ 10.0 g/dl. Use of transfusion or other intervention to achieve this hemoglobin level is acceptable.
• * Blood urea nitrogen ≤ 30mg/dl and creatinine ≤ 1.7 mg/dl
• * Bilirubin ≤ 2.0 mg/dl, Aspartate aminotransferase/ Alanine aminotransferase (AST/ALT) ≤ 3x upper limit of normal
• * Electrocardiogram without evidence of acute cardiac ischemia
• * Prothrombin time/international normalized ratio (PT INR) \<1.4
• * Women of childbearing potential and male participants must practice adequate contraception.
• * For women of childbearing age, negative pregnancy test within 14 days prior to registration
• * Subjects must have the ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

• * Participants not eligible to obtain MRI with and without contrast
• * Recurrent High grade gliomas (HGG)
• * Cerebral edema, grade 3 or greater prior to surgery
• * Post-operative complications including significant neurological decline or hemorrhage that causes a drop in KPS to less than 60 or renders the patient not suitable for chemoradiation as determined by their treating physician
• * Severe co-morbidity that would confer excess risk of surgery, radiation or chemotherapy, as determined by the treating physician.
• Any other major medical illnesses or psychiatric impairments that in the investigator's opinion will prevent administration of completion of protocol therapy
• * Any other major medical illnesses or psychiatric impairments that in the investigator's opinion will prevent administration or completion of protocol therapy.
• * Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic.
• * Participants receiving other investigational agents.